Diagnostic sensitivity of 2-day cardiopulmonary exercise testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Nelson, Maximillian J, Buckley, Jonathan D, Thomson, Rebecca L et al. · Journal of translational medicine · 2019 · DOI
Quick Summary
Researchers tested whether a simple exercise test could help diagnose ME/CFS. They had patients and healthy people exercise on a stationary bike on two consecutive days and measured how their performance changed. ME/CFS patients showed a larger drop in exercise capacity on the second day compared to healthy people, suggesting this difference might be a useful diagnostic tool.
Why It Matters
ME/CFS lacks objective diagnostic biomarkers, making diagnosis difficult and often delayed. This study identifies a potential objective measurement—the specific pattern of decline in exercise capacity over consecutive days—that could assist clinicians in confirming ME/CFS diagnosis and reducing diagnostic uncertainty for patients.
Observed Findings
Work rate at ventilatory threshold decreased from day 1 to day 2 in both groups, but the decrease was significantly greater in ME/CFS patients (group × time interaction, p < 0.01).
ROC curve analysis identified optimal sensitivity and specificity when WR at VT declined by 6.3% to 9.8% between consecutive test days.
No significant interaction effects were found for heart rate, ventilation, or ratings of perceived exertion between groups across test days.
Inferred Conclusions
A 6.3–9.8% decrease in work rate at ventilatory threshold on the second consecutive day of CPET may serve as an objective biomarker for ME/CFS diagnosis.
The pattern of exercise intolerance on repeated testing appears to differentiate ME/CFS patients from healthy controls more effectively than single-day exercise metrics.
Two-day consecutive CPET protocols may improve diagnostic accuracy by capturing the characteristic post-exertional deterioration seen in ME/CFS.
Remaining Questions
Can these cut-off values (6.3–9.8% decline) be validated in larger, diverse patient cohorts to confirm sensitivity and specificity?
Does this decline pattern occur in other post-viral or fatigue-related conditions, or is it specific to ME/CFS?
What is the biological mechanism underlying this greater decline in ventilatory threshold on the second test day in ME/CFS patients?
What This Study Does Not Prove
This small pilot study does not establish that 2-day CPET decline is a definitive diagnostic test; larger, prospective validation studies are needed before clinical implementation. The findings do not explain the biological mechanism causing this exercise decline, nor do they determine whether this pattern is specific to ME/CFS or might occur in other conditions. The cross-sectional design cannot establish whether the decline is a cause or consequence of ME/CFS.